Skip to main content
SpringerLink
Log in
Book cover

Therapiekonzepte Onkologie pp 712–747Cite as

Regionale Therapie hepatischer Tumoren

  • Chapter

  • 66 Accesses

Zusammenfassung

Fernmetastasen solider Tumoren sind — auch bei unilokulärer Manifestation — als Hinweis auf eine systemische Tumorerkrankung anzusehen und können mittels Operation oder Radiotherapie nur selten kurativ behandelt werden. In einzelnen Fällen, in denen die Metastasierung in nur einem Organ bzw. einer umschriebenen anatomischen Region auftritt, ist eine regionale Therapie zur erwägen. Das Konzept einer regionalen Tumorbehandlung wurde in den frühen 50iger Jahren von Kopp et al. [1 J und Bierman et al. [2] entwickelt, die Stickstoff-Lost intraarteriell in verschiedene Tumoren infundierten. Die arterielle Leberperfusion mittels Zytostatika wurde von Watkins und Sullivan [3, 4] entwickelt, die über einen Teflon-Katheter 5-Fluorouracil (5-FU) oder 2’-Deoxy-5-Fluorouridin (FUDR) mit Hilfe einer externen Infusionspumpe in die Arteria hepatica communis applizierten. Obwohl diese ersten Therapieversuche in zahlreichen Komplikationen resultierten, stellt die arterielle Leberinfusion (hepatic arterial infusion; HAI) aufgrund technischer Weiterentwicklungen heute für zahlreiche Patienten eine erwägenswerte Therapieoption dar. Die regionale Therapie hepatischer Metastasen mit Standard-Chemotherapeutika ist aus mehreren Gründen durchführbar: einer zweifachen Blutversorgung der Leber; einer hohen Gewebetoleranz gegenüber den meisten chemotherapeutischen Substanzen; geeigneter Pharmakokinetik der am häufigsten für die HAI-Therapie angewendeten Zytostatika.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Klopp CT, Alford TL, Bateman J, Berry GN, Winship T (1950) Fractionated intra-arterial cancer chemotherapy with methyl-bis-amine hydrochloride: A preliminary report. Ann Surg 132:811 –832

    PubMed  CAS  Google Scholar 

  2. Bierman HR, Byron RL, Miller FR et al. (1950) Effects of intra-arterial administration of nitrogen mustard. Am J Med 8:535

    PubMed  CAS  Google Scholar 

  3. Watkins E Jr, Sullivan RD (1964) Cancer chemotherapy by prolonged arterial infusion. Surg Gynecol Obstet 118:3–19

    PubMed  Google Scholar 

  4. Sullivan RD, Zurek WZ (1965) Chemotherapy for liver cancer by protracted ambulatory infusion. JAMA 194:481–486

    PubMed  CAS  Google Scholar 

  5. Aeberhard P (1988) Intra-arterial chemotherapy without pump. Antibiot Chemother 210:41–50

    Google Scholar 

  6. Honjo I, Matsumura H (1965) Vascular distribution of hepatic tumors. Rev Intl Hepatol 15:681–690

    CAS  Google Scholar 

  7. Ackerman NB (1975) The blood supply of experimental liver metastases. IV changes in vascularity with increasing tumor growth. Surgery 75:589–596

    Google Scholar 

  8. Sigurdson ER, Ridge JA, Kemeny N, Daly JM (1987) Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 5:1836–1840

    PubMed  CAS  Google Scholar 

  9. Burgener FA, Violante MR (1979) Comparison of hepatic VX2 carcinomas after intra-arterial, intraportal and intraparenchymal tumor cell injection. An angiographic and computed tomographic study in the rabbit. Invest Radiol 14:410–414

    PubMed  CAS  Google Scholar 

  10. Pickren JW, Tsukada Y, Lane WW (1982) Liver metastasis: Analysis of autopsy data. In: Weiss L and Gilbert H (eds) Liver Metastasis. Boston: G.K. Hall Medical Publishers, 2–18

    Google Scholar 

  11. Balch CM, Houghton A, Peters L (1989) Cutaneous Melanoma. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology. Philadelphia: J.B. Lippincott Co, 1499–1542

    Google Scholar 

  12. Henderson IC, Harris JR, Kinne DW, Hellman S (1989) Cancer of the Breast. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology. Philadelphia: J.B. Lippincott Co, 1197–1268

    Google Scholar 

  13. Jaffe BM, Donegan WL, Watson F, Spratt JS Jr (1968) Factors influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet 127:1 – 11

    PubMed  CAS  Google Scholar 

  14. Bengmark S, Brix M, Borjesson B, Hafstrom L, Olsson A (1970) Treatment of hepatic tumors. Digestion 3:309–317

    PubMed  CAS  Google Scholar 

  15. Kemeny N, Niedzwiecki D, Shurgot B, Oderman P (1989) Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement. Cancer 63:742–747

    PubMed  CAS  Google Scholar 

  16. Cady B, Monson DO, Swinton NW (1970) Survival of patients after colonic resection for carcinoma with simultaneous liver metastases. Surg Cynecol Obstet 131:697–700

    CAS  Google Scholar 

  17. Foster JH (1978) Survival after liver resection for secondary tumors. Am J Surg 135:389–394

    PubMed  CAS  Google Scholar 

  18. Bengmark S, Hafstrom L (1969) The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 23:198–202

    PubMed  CAS  Google Scholar 

  19. Wanebo HJ, Semoglou C, Attiyeh F, Stearns MJ Jr (1978) Surgical management of patients with primary operable colorectal cancer and synchronous liver metastases. Am J Surg 135:81–85

    PubMed  CAS  Google Scholar 

  20. Wood CB, Gillis CR, Blumgart LH (1976) A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 2 : 285–288

    PubMed  CAS  Google Scholar 

  21. Kemeny N, Schneider A (1989) Regional treatment of hepatic metastases and hepatocellular carcinoma. Curr Probl Cancer 13:197–283

    PubMed  CAS  Google Scholar 

  22. Latham L Jr, Foster JH (1967) Hepatic resection for metastatic cancer. Am J Surg 113:51–557

    Google Scholar 

  23. Frei E III, Canellos GP (1980) Dose: A critical factor in cancer chemotherapy. Am J Med 69:585–594

    PubMed  Google Scholar 

  24. Ensminger WD, Gyves JW (1983) Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 10:176–182

    PubMed  CAS  Google Scholar 

  25. Sigurdson ER, Ridge JA, Daly JM (1986) Fluorodeoxyrudine uptake by human colorectal hepatic metastases after hepatic artery infusion. Surgery 100:285–291

    PubMed  CAS  Google Scholar 

  26. Hohn DC, Shea WJ, Gemlo BT et al. (1988) Complications and toxicities of hepatic arterial chemotherapy. Contr Oncol 29:169–180

    Google Scholar 

  27. Northover JM, Terblanche J (1979) A new look at the arterial supply of the bile duct in man and its surgical implications. Br J Surg 66:379–384

    PubMed  CAS  Google Scholar 

  28. Doppman JL, Girton ME (1984) Bile duct scarring following ethanol embolization of the hepatic artery: An experimental study in monkeys. Radiology 152:621–626

    PubMed  CAS  Google Scholar 

  29. Pettavel J, Gardiol D, Bergier N, Schnyder P (1988) Necrosis of main bile ducts caused by hepatic artery infusion of 5-fluoro-2-deoxyuridine. Reg Cancer Treat 1:83–92

    Google Scholar 

  30. Von Roemeling R, Hrushesky WJ (1990) Determination of therapeutic index of floxuridine by its circadian infusion pattern. J Natl Cancer Inst 82:386–393

    Google Scholar 

  31. Patt YZ, Maglivit GM (1991) Arterial chemotherapy in the management of colorectal cancer: An overview. Semin Oncol 18:478–490

    PubMed  CAS  Google Scholar 

  32. Hohn DC, Rayner AA, Economou JS, Ignoffo RJ, Lewis BJ, Stagg RJ (1986) Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion. Cancer 57:465–470

    PubMed  CAS  Google Scholar 

  33. Kemeny N, Seiter K, Niedzwiecki D, Chapman D, Sigurdson E, Cohen A, Botet J, Oderman P, Murray P (1992) A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 69:327–334

    PubMed  CAS  Google Scholar 

  34. Stagg RJ, Venook Ap, Chase IL, Lewis BJ, Warren RS, Roph M, Mulvihill SJ, Grobman BJ, Rayner AA, Hohn DC (1991) Alternating hepatic intra-arterial floxuridine and fluorouracil: A less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst 8:423–428

    Google Scholar 

  35. Kemeny MM, Goldberg D, Beatty ID, Blayney D, Browning S, Doroshow J, Ganteauma L, Hill RL, Kokal WA, Riihimaki DU et al. (1986) Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. Cancer 57:492–498

    PubMed  CAS  Google Scholar 

  36. Ensminger WD (1984) Intra-arterial therapy of hepatic metastases. In: Howell SB (ed) Intra-arterial and intracavitary cancer chemotherapy. Boston: Martinus Nijhoff Publishers, 71–76

    Google Scholar 

  37. Niederhuber JE, Ensminger W, Gyves J, Thrall J, Walker S, Cozzi E (1984) Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer 53: 1336–1343

    PubMed  CAS  Google Scholar 

  38. Shepard KV, Levin B, Karl RC, Fasintuch J, DuBrow RA, Hagle M, Cooper RM, Beschorner J, Stablein D (1985) Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump. J Clin Oncol 3:161–169

    PubMed  CAS  Google Scholar 

  39. Weiss GR, Garnick MB, Osteen RT, Steele GD Jr, Wilson RE, Schade D, Kaplan WD, Boxt LM, Kandarpa K, Mayer RJ et al. (1983) Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump. J Clin Oncol 1:337–344

    PubMed  CAS  Google Scholar 

  40. Ramming KP, O’Toole K (1986) The use of the implantable chemoinfusion pump in the treatment of hepatic metastases of colorectal cancer. Arch Surg 121: 1400–1444

    Google Scholar 

  41. Cohen AM, Kaufman SD, Wood WC, Greenfield AJ (1983) Regional hepatic chemotherapy using an implantable drug infusion pump. Am J Surg 145:529–533

    PubMed  CAS  Google Scholar 

  42. Hohn DC, Melnick J, Stagg R, Altman D, Friedman M, Ignoffo R, Ferrell L, Lewis B (1985) Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J Clin Oncol 3:98–102

    PubMed  CAS  Google Scholar 

  43. Machover D, Goldschmidt E, Chollet P, Metzger G, Zittoun J, Marquet J, Vandenbulcke IM, Misset JL, Schwarzenberg L, Fourtillan JB et al. (1986) Treatment of advanced colorectal and gastric adenocarcinoma with 5-fluorouracil and high dose folinic acid. J Clin Oncol 4:685–696

    PubMed  CAS  Google Scholar 

  44. Smiley S, Schouten J, Chang A et al. (1981) Intrahepatic arterial infusion with 5-Fu for liver metastases of colorectal carcinoma [abstract]. In: Proc Am Ass Cancer Res 22:391

    Google Scholar 

  45. Reed ML, Vaitkeviciius VK, Al-Sarraf M, Vaughn CB, Singhakowinta A, Sexon-O’Porte M, Izbicki R, Baker L, Straatsma GW (1981) The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: Ten year results of 124 patients in a prospective protocol. Cancer 47: 402–409

    PubMed  CAS  Google Scholar 

  46. Ensminger W, Niederhuber J, Dakhil S, Thrall J, Wheeler R (1981) Totally implanted drug delivery system for hepatic arterial chemotherapy. Cancer Treat Rep 65:393–400

    PubMed  CAS  Google Scholar 

  47. Doci R, Bignami P, Quagliuolo V et al. (1990) Continuous hepatic arterial infusion with 5-fluorodeoxyuridine for treatment of colorectal metastases. Reg Cancer Treat 3:13–18

    Google Scholar 

  48. Kemeny N, Daly J, Oderman P, Shike M, Chun H, Petroni G, Geller N (1984) Hepatic artery pump infusion toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol 2:595–600

    PubMed  CAS  Google Scholar 

  49. Hohn DC, Stagg RJ, Price DC, Lewis BJ (1985) Avoidance of gastroduodenal toxicity in patients receiving hepatic arterial 5-fluoro-2’-deoxyuridine. J Clin Oncol 3:1257–1260

    PubMed  CAS  Google Scholar 

  50. Ensminger W, Niederhuber J, Gyves JW et al. (1982) Effective control of liver metastases from colon cancer with an implanted system for hepatic arterial chemotherapy [abstract]. In: Proc Am Soc Clin Oncol 1 :A94

    Google Scholar 

  51. Buroker T, Samson M, Correa J, Fraile R, Vaitkevicius VK (1976) Hepatic artery infusion of 5-FUDR after prior systemic 5-fluorouracil. Cancer Treat Rep 60: 1277–1279

    PubMed  CAS  Google Scholar 

  52. Petrek JA, Minton JP (1979) Treatment of hepatic metastases by percutaneous hepatic arterial infusion. Cancer 43:2182–2188

    PubMed  CAS  Google Scholar 

  53. Huberman MS (1983) Comparison of systemic chemotherapy with hepatic arterial infusion in metastatic colorectal carcinoma. Semin Oncol 10:238–248

    PubMed  CAS  Google Scholar 

  54. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P (1987) Intrahepatic or systemic fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 107:459–465

    PubMed  CAS  Google Scholar 

  55. Hohn DC, Stagg R, Friedman MA, Hannigan JR Jr, Rayner A, Ignoffo RJ, Acord P, Lewis BJ (1989) A randomized trial of continuous intravenous versus hepatic intra-arterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group Trial. J Clin Oncol 7:1646–1654

    PubMed  CAS  Google Scholar 

  56. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM (1987) A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206:685–693

    PubMed  CAS  Google Scholar 

  57. Martin JK Jr, O’Connell MJ, Wieand HS, Fitzgibbons RJ Jr, Mailliard JA, Rubin J, Nagorney DM, Tschetter LK, Krook JE (1990) Intra-arterial floxuridine versus systemic fluorouracil for hepatic metastases from colorectal cancer: A randomized trial. Arch Surg 125:1022–1027

    PubMed  Google Scholar 

  58. Roughier PH, Jay JM, Olivier JE et al. (1990) A controlled multicentric trial of intrahepatic chemotherapy versus standard palliative treatment for colorectal liver metastases [abstract]. In: Proc Am Soc Clin Oncol 9:A 104

    Google Scholar 

  59. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J (1994) Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344:1255–1260

    PubMed  CAS  Google Scholar 

  60. Buyse M (1996) Reappraisal of hepatic arterial infusion in the treatment of non-resectable liver metastases from colorectal cancer. J Natl Cancer Inst 88:252–258

    Google Scholar 

  61. Durandzaleski I, Roche B, Buyse M, Carlson R, O’Connell MJ, Rougier P, Chang AE, Sondak VK, Kemeny MM, Allenmersh TG, Fagniez PL, Lebourgeois JP, Piedbois P (1997) Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. J Natl Cancer Inst 89:790–795

    CAS  Google Scholar 

  62. Patt YZ, Hoque A, Lozano R, Pazdur R, Chase J, Carrasco H, Chuang V, Delpassand ES, Ellis L, Curley S, Roh M, Jones DV (1997) Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alpha-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin. J Clin Oncol 15:1432–1438

    PubMed  CAS  Google Scholar 

  63. Hartmann JT, Schmoll E, Bokemeyer C, Fety R, Lucas C, Degay L, Schmoll HF (1997) Hepatic arterial infusion of the nitrosourea derivative fotemustine for the treatment of liver metastases from colorectal carcinoma. Oncol Rep 4:167–172

    PubMed  CAS  Google Scholar 

  64. Sciarrino E, Simonetti R, LeMoli S, Pagliaro L (1985) Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer 56:2751–2755

    PubMed  CAS  Google Scholar 

  65. Chlewbowski RT, Brzechwa-Adjukiewicz A, Cowden A, Block JB, Tong M, Chan KK (1984) Doxorubicin (75 mg/m2) for hepatocellular carcinoma: Clinical and pharmacokinetic results. Cancer Treat Rep 68:487–491

    Google Scholar 

  66. Ihde DC, Kane RC, Cohen MN, McIntire KR, Minna JD (1977) Adriamycin therapy in American patients with hepatocellular carcinoma. Cancer Treat Rep 61:1385–1387

    PubMed  CAS  Google Scholar 

  67. Bing-Hui Y, Zhao-You T (1989) Randomized clinical trial of cisplatin in the treatment of hepatocellular carcinoma. In: Zhao-You T, Meng-Chao W, Sui-Sheng X (Eds) Primary Liver Cancer. New York: Springer Verlag, 434–437

    Google Scholar 

  68. Okada S, Okazaki N, Nose H, Shimada Y, Yoshimori M, Aoki K (1993) A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology 50:22–26

    PubMed  CAS  Google Scholar 

  69. Falkson G, Moertel CG, Lavin P, Pretorius FJ, Carbone PP (1978) Chemotherapy studies in primary liver cancer: A prospective randomized clinical trial. Cancer 42:2149–2156

    PubMed  CAS  Google Scholar 

  70. Melia WM, Johnson PJ, Williams R (1983) Induction of remission in hepatocellular carcinoma. A comparison of etoposide (VP 16) with Adriamycin. Cancer 51:206–210

    PubMed  CAS  Google Scholar 

  71. Shiu WC (1992) Primary liver cancer in Hong Kong. Cancer Chemother Pharmacol 31 (Suppl 1):S143–S145

    Google Scholar 

  72. Farinati F, Salvagnini M, de Maria N, Fornasiero A, Chiaramonte M, Rossaro L, Naccarato R (1990) Unresectable hepatocellular carcinoma: A prospective controlled trial with tamoxifen. J Hepatol 11:297–301

    PubMed  CAS  Google Scholar 

  73. Engstrom PF, Levin B, Moertel CG, Schutt A (1990) A phase II trial of tamoxifen in hepatocellular carcinoma. Cancer 65:2641–2643

    PubMed  CAS  Google Scholar 

  74. Gupta S, Korula J (1988) Failure of ketoconazole as anti-androgen therapy in nonresectable primary hepatocellular carcinoma. J Clin Gastroenterol 10:651 – 654

    PubMed  CAS  Google Scholar 

  75. The Gastrointestinal Tumor Study Group (1990) A prospective trial of recombinant human interferon alpha 2b in previously untreated patients with hepatocellular carcinoma. Cancer 66:135–139

    Google Scholar 

  76. Creagan ET, Long HJ, Frytak S, Moertel CG (1988) Recombinant leucocyte A interferon with doxorubicin. A phase I study in advanced solid neoplasms and implications for hepatocellular carcinoma. Cancer 61:19–22

    PubMed  CAS  Google Scholar 

  77. Lai CL, Wu PC, Lok AS, Lin HJ, Ngan H, Lau JY, Chung HT, Ng MM, Yeoh EK, Arnold M (1989) Recombinant a 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: A prospective randomized trial. Br J Cancer 60:928–933

    PubMed  CAS  Google Scholar 

  78. Patt YZ, Yoffe B, Charnsangavej C, Pazdur R, Rischer H, Cleary K, Roh M, Smith R, Noonan CA, Levin B (1993) Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b. Cancer 72:2574–2582

    PubMed  CAS  Google Scholar 

  79. Lotze MT, Flickinger JC, Carr BL (1993) Hepatobiliary neoplasms. In: DeVita VT, Hellman S, Rosenberg SA (Eds) Cancer: Principles and Practice of Oncology, fourth edition. Philadelphia: J.B. Lippincott Co, 883–914

    Google Scholar 

  80. Al-Sharraf M, Go TS, Kithier K, Vaitkevicius VK (1974) Proceedings: Primary liver cancer. A review of the clinical features, blood groups, serum enzymes, therapy, and survival of 65 cases. Cancer 33:574–584

    Google Scholar 

  81. Malik IA, Khan WA, Haq S, Sabih M (1997) A prospective phase II trial to evaluate the efficacy and toxicity of hepatic arterial infusion of ifosfamide in patients with inoperable localized hepatocellular carcinoma. Am J Clin Oncol 20:289–292

    PubMed  CAS  Google Scholar 

  82. Rougier P, Pelletier G, Ducreaux M, Gay F, Luboinski M, Hagége, Dao T, Van Steenbergen V, Buffet C, Adler M, Pignon JP, Roche A, et le groupe CHC2, Villejuif, Le Kremlin Bicêtre, Creteil, Caen, Louvain, France and Bruxelles, Belgium (1997) Unresectable hepatocellular carcinoma: lack of efficacy of lipiodol chemoembolization. Final results of a multicenter randomized trial. In: Proc Am Soc Clin Oncol 16:279 a

    Google Scholar 

  83. Patt YZ, Chaghorn L, Charnsangaveej C, Soski M, Cleary K, Mavligit GM (1988) Hepatocellular cancer. A retrospective analysis of treatments to manage disease confined to the liver. Cancer 61:1884–1888

    PubMed  CAS  Google Scholar 

  84. Patt YZ, Charnsangavej C, Yoffe B, Smith R, Lawrence D, Chuang V, Carrasco H, Roh M, Chase J, Fischer H, Jones D, Levin B (1994) Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: Effects of hepatitis B and C viral infection on drug toxicity and patient survival. J Clin Oncol 12:1204–1211

    PubMed  CAS  Google Scholar 

  85. Carter SK (1972) Single and combination nonhormonal chemotherapy in breast cancer. Cancer 30:1543–1555

    PubMed  CAS  Google Scholar 

  86. Kemeny N (1983) The systemic chemotherapy of hepatic metastases. Semin Oncol 10:148–158

    PubMed  CAS  Google Scholar 

  87. Fraschini G, Fleishman G, Charnsangavej C, Carrasco CH, Hortobagyi GN (1987) Continuous 5-day infusion of vinblastine for percutaneous hepatic arterial chemotherapy for metastatic breast cancer. Cancer Treat Rep 71:1001–1005

    PubMed  CAS  Google Scholar 

  88. Fraschini G, Fleishman G, Yap HY, Carrasco CH, Charnsangavej C, Patt YZ, Hortobagyi GN (1987) Percutaneous hepatic arterial infusion of cisplatin for metastatic breast cancer. Cancer Treat Rep 71:313–315

    PubMed  CAS  Google Scholar 

  89. Fraschini G, Charnsangavej C, Carrasco CH, Buzdar AU, Labboury KW, Hortobagyi GN (1988) Percutaneous hepatic arterial infusion of cisplatin-vinblas-tine for refractory breast cancer metastatic to the liver. Am J Clin Oncol 11:34–38

    PubMed  CAS  Google Scholar 

  90. Fraschini G, Yap HY, Hortobagyi GN, Buzdar A, Blumenschein G (1985) Five-day continuous-infusion vinblastine in the treatment of breast cancer. Cancer 56:225–229

    PubMed  CAS  Google Scholar 

  91. Arai Y, Kido C, Endo T et al. (1988) Hepatic arterial infusion chemotherapy for liver metastases from colon, gastric, and breast cancer [abstract]. In: Proc Am Soc Clin Oncol 7: A 102

    Google Scholar 

  92. Fraschini G, Yap H-Y, Chuang VA (1983) Remission consolidation in metastatic breast cancer to the liver with hepatic arterial infusion chemotherapy [abstract]. In: Proc Am Soc Clin Oncol 2: A 107

    Google Scholar 

  93. Mattsson W, Lonsson K, Hellekant C, Hallsten L (1980) Short-term intra-arterial mitomycin C in hepatic metastases. Acta Radiol 19:321–325

    CAS  Google Scholar 

  94. Lange MK, Minton JP (1990) Intrahepatic chemotherapy salvage following systemic chemotherapy failure for metastatic breast cancer to the liver [abstract]. In: Proc Am Soc Clin Oncol 9: A 166

    Google Scholar 

  95. Ansfield FJ, Ramirez G, Skibba JL, Bryan GT, Davis HL Jr, Wirtanen GW (1972) Intrahepatic arterial infusions with 5-fluorouracil. Wis Med J 71:170

    PubMed  CAS  Google Scholar 

  96. Davis HL Jr, Ramirez G, Ansfield FJ (1974) Adenocarcinomas of the stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoro-pyrimidine therapy. Cancer 33:193–197

    PubMed  Google Scholar 

  97. Tandon RN, Bunnell IL, Cooper RG (1973) The treatment of metastatic carcinoma of the liver by percutaneous selective hepatic artery infusion of 5-fluoro-uracil. Surgery 73:118–121

    PubMed  CAS  Google Scholar 

  98. Bengmark S, Andren-Sandberg A (1983) Infusion chemotherapy in inoperable pancreatic carcinoma. Recent Results Cancer Res 86:13–14

    PubMed  CAS  Google Scholar 

  99. Aigner KR, Muller H, Bassermann R (1990) Intra-arterial chemotherapy with MMC, CDDP, and 5-FU for nonresectable pancreatic cancer — A phase II study. Reg Cancer Treat 3:1–6

    Google Scholar 

  100. Kessinger A, Foley JF, Lemon HM (1983) Therapy of malignant APUD cell tumors. Effectiveness of DTIC. Cancer 51:790–794

    PubMed  CAS  Google Scholar 

  101. Kvols LK, Buck M (1987) Chemotherapy of metastatic carcinoid and islet cell tumors. A review. Am J Med 82:77–83

    PubMed  CAS  Google Scholar 

  102. Moertel CG, Hanley JA, Johnson LA (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of islet-cell carcinoma. N Engl J Med 303:1189–1194

    PubMed  CAS  Google Scholar 

  103. Moertel CG (1975) Clinical management of advanced gastrointestinal cancer. Cancer 36:675–682

    PubMed  CAS  Google Scholar 

  104. Kvols LK (1986) Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy. Am J Med 81 (Suppl 6B) :49–55

    PubMed  CAS  Google Scholar 

  105. Moertel CG (1983) Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1:727–740

    PubMed  CAS  Google Scholar 

  106. Moertel CG, Hanley JA (1979) Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 2:327–334

    PubMed  CAS  Google Scholar 

  107. Engstrom PF, Lavin PT, Moertel CG, Folsch E, Douglass HO Jr (1984) Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 2:1255–1259

    PubMed  CAS  Google Scholar 

  108. Reed ML, Kuipers FM, Vaitkevicius VK et al. (1963) Treatment of disseminated carcinoid tumors including hepatic artery catheterization. N Engl J Med 269: 1005–1010

    PubMed  CAS  Google Scholar 

  109. Martin JK Jr, Moertel CG, Adson MA, Schutt AJ (1983) Surgical treatment of functioning metastatic carcinoid tumors. Arch Surg 118:537–542

    PubMed  Google Scholar 

  110. Carrasco CH, Charnsangavej C, Ajani JA, Samaan NA, Richli W, Wallace S (1986) The carcinoid syndrome: Palliation by hepatic artery embolization. Am J Roentgenol 147:149–154

    CAS  Google Scholar 

  111. Ajani JA, Carrasco CH, Charnsangavej C, Samaan NA, Levin B, Wallace S (1988) Islet cell tumors metastatic to the liver: Effective palliation by sequential hepatic artery embolization. Ann Intern Med 108:340–344

    PubMed  CAS  Google Scholar 

  112. Clouse ME, Lee RG, Duszlak T, Lokich JJ, Alday MT (1983) Hepatic artery embolization for metastatic endocrine-secreting tumors of the pancreas. Report of two cases. Gastroenterology 85:1183–1186

    PubMed  CAS  Google Scholar 

  113. Moertel CG (1987) Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 5:1502–1522

    PubMed  CAS  Google Scholar 

  114. Patt YZ, Jones DV Jr, Hoque A, Lozano R, Markowitz A, Raijman I, Lynch P, Charnsangavej C (1996) Phase II trial of intravenous flourouracil and subcutaneous interferon alpha-2b for biliary tract cancer. J Clin Oncol 14:2311–2315

    PubMed  CAS  Google Scholar 

  115. Misra NC, Jaiswal MS, Singh RV, Das B (1977) Intrahepatic arterial infusion of combination of mitomycin-C and 5-fluorouracil in the treatment of primary and metastatic liver carcinoma. Cancer 39:1425–1429

    PubMed  CAS  Google Scholar 

  116. Mavligit GM, Zukiwski AA, Salem PA, Lamki L, Wallace S (1991) Regression of hepatic metastases from gastrointestinal leiomyosarcoma after hepatic arterial chemoembolization. Cancer 68:321–323

    PubMed  CAS  Google Scholar 

  117. Khansur T, Patel V, Newcomb M, Balducci L (1987) Hepatic intra-arterial Adriamycin in metastatic leiomyosarcoma: Exploiting the steep dose-response curve. J Surg Oncol 36:76–79

    PubMed  CAS  Google Scholar 

  118. Carrasco CH, Wallace S, Charnsangavej C, Papadopoulos NE, Patt YZ, Mavligit GM (1986) Treatment of hepatic metastases in ocular melanoma. Embolization of the hepatic artery with polyvinyl sponge and cisplatin. JAMA 255:3152–3154

    PubMed  CAS  Google Scholar 

  119. Mavligit GM, Charnsangavej C, Carrasco CH, Patt YZ, Benjamin RS, Wallace S (1988) Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 260: 974–976

    PubMed  CAS  Google Scholar 

  120. Kuwamitsu O, Kubota Y, Miura T et al. (1990) Intra-arterial chemotherapy combined with surgery for liver metastases of renal cell carcinoma. Reg Cancer Treat 3:166–1678

    Google Scholar 

  121. Kawai K, Saski A, Nishijima Y, Kikuchi K, Ohtani M, Rinshou K, Koiso K, Adachi S, Ishikawa A, Iwasaki Y (1990) A case of nonseminomatous testicular tumor liver metastases, treated by intrahepatic arterial cisplatinum-diaminedichloride infusion. Eur Urol 18:234–236

    PubMed  CAS  Google Scholar 

  122. Fujii S, Nakajima K, Ueno K, Sugai Y, Adachi M (1989) A case of intra-arterial infusion chemotherapy in small cell lung cancer with liver metastases. Gan To Kagaku Ryoho 16:3627–3630

    PubMed  CAS  Google Scholar 

  123. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endo-toxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sei USA 72:3666–3670

    CAS  Google Scholar 

  124. Shirai T, Yamaguchi H, Ito H, Todd CW, Wallace RB (1985) Cloning and expression in Escherichia coli of the gene for human tumor necrosis factor. Nature 313:803–806

    PubMed  CAS  Google Scholar 

  125. Creagan ET, Kovach JS, Moertel CG, Frytak S, Kvols LK (1988) A phase I clinical trial of recombinant human tumor necrosis factor. Cancer 62:2467–2471

    PubMed  CAS  Google Scholar 

  126. Creaven PJ, Brenner DE, Cowens JW, Huben RP, Wolf RM, Kaita H, Arbuck SG, Rrazack MS, Proefrock AD (1989) A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days. Cancer Chemother Pharmacol 23: 186–191

    PubMed  CAS  Google Scholar 

  127. Wiedenmann B, Reichardt P, Rath U, Theilmann L, Schule B, Ho AD, Schlick E, Kempeni J, Hunstein W, Kommereil B (1989) Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas. J Cancer Res Clin Oncol 115:189–192

    PubMed  CAS  Google Scholar 

  128. Kimura K, Taguchi T, Urushizaki I, Ohno R, Abe O, Fure H, Hattori T, Ichihashi H, Onoguchi K, Majima H et al. (1987) Phase I study of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 20:223–229

    PubMed  CAS  Google Scholar 

  129. Pfreundschuh MG, Steinmetz HT, Tüschen R, Schenk V, Kiehl V, Schaadt M (1989) Phase I study of intratumoral application of recombinant human tumor necrosis factor. Eur J Cancer Clin Oncol 25:379–388

    PubMed  CAS  Google Scholar 

  130. Bartsch HH, Pfizenmaier K, Schroeder M, Nagel GA (1989) Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies. Eur J Cancer Clin Oncol 25: 287–291

    PubMed  CAS  Google Scholar 

  131. Selby P, Hobbs S, Viner C, Lackson E, Jones A, Newell D, Calvert AH, McElwain T, Fearon K, Humphreys J et al. (1987) Tumor necrosis factor in man: Clinical and biological observations. Br J Cancer 56:803–808

    PubMed  CAS  Google Scholar 

  132. Mavligit GM, Zukiwski AA, Charnsangavej C, Carrasco CH, Wallace S, Gutterman JU (1992) Regional biologic therapy. Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases. Cancer 69:557–561

    PubMed  CAS  Google Scholar 

  133. Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193:1007 – 1008

    PubMed  CAS  Google Scholar 

  134. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-acti-vated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823–1841

    PubMed  CAS  Google Scholar 

  135. Rosenberg SA, Lotze MT, Muul LM, Change AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897

    PubMed  CAS  Google Scholar 

  136. Klasa RJ, Silver HK, Kong S (1990) In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy. Cancer Res 50:4906–4910

    PubMed  CAS  Google Scholar 

  137. Klasa RJ, Silver HKB (1989) Phase 1–2 trial of interleukin-2 (IL-2) splenic artery perfusion in advanced malignancy [abstract]. In: Eur J Cancer Clin Oncol 25: 379–388

    Google Scholar 

  138. Klasa RJ, Silver HKB (1989) Phase 1–2 trial of interleukin-2 (IL-2) splenic artery perfusion in advanced malignancy [abstract]. In: Eur J Cancer Clin Oncol 8:A686

    Google Scholar 

  139. Okuno K, Ohnishi H, Koh K, Shindo H, Yoshioka H, Yasutomi M (1992) Clinical trials of intrasplenic arterial infusion of interleukin-2 (IS-IL-2) to patients with advanced cancer. Biotherapy 4:257–265

    PubMed  CAS  Google Scholar 

  140. Thatcher N, Dazzi H, Johnson RJ, Russell S, Ghosh AK, Moore M, Chadwick G, Craig RD (1989) Recombinant interleukin-2 (rIL-2) given intra-splenically and intravenously for advanced malignant melanoma. A phase I and II study. Br J Cancer 60:770–774

    PubMed  CAS  Google Scholar 

  141. Mavligit GM, Zukiwski AA, Gutterman JU, Salem P, Charnsangavej C, Wallace S (1990) Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastases. J Clin Oncol 8:319–324

    PubMed  CAS  Google Scholar 

  142. Yamamoto M, Izzuka H, Fujii H, Matsuda M, Miura K (1993) Hepatic arterial infusion of interleukin-2 in advanced hepatocellular carcinoma. Acta Oncol 32 : 43–51

    PubMed  CAS  Google Scholar 

  143. Hazama S, Oka M, Shimizu R, Yano K, Yoshino S, Lizuka N, Murakami T, Suzuki T (1990) Intra-arterial combination immunotherapy in hepatocellular carcinoma. Gan To Kagaku Ryoho 17:1638–1642

    PubMed  CAS  Google Scholar 

  144. Miya K, Saji S, Furuta T, Tanemura H, Azuma S, Umemoto T, Kunieda K, Takao H, Sugiyama Y, Kawai M et al. (1991) Therapeutic effect of transarterial infusion immunochemotherapy for metastatic liver cancer. Gan To Kangaku Ryoho 18: 1992–1995

    CAS  Google Scholar 

  145. Okuno K, Ohnishi H, Nakajima I, Yagita M, Yasutomi M (1992) Intrahepatic infusion of interleukin-2 (IL-2) with mitomycin C (MMC)/5-fluorouracil (5-FU) through an implantable pump for the treatment of liver metastases [abstract]. In: Proc Am Ass Cancer Res 33 : A 1475

    Google Scholar 

  146. Cohen RJ, Minor DR, Okdham RK, Barth N, Birch R, West WH (1990) Treatment of refractory cancer by intravenous interleukin-2 (IL-2), together with lym-phokine-activated killer (LAK) cells administered by direct regional infusion [abstract]. In: Proc Am Soc Clin Oncol 9: A 748

    Google Scholar 

  147. Han FG (1991) Treatment of advanced liver cancer by autologous and/or homologous LAK cells combined with human natural IL-2. Chung Hua Chung Liu Tsa Chih 13:145–148

    PubMed  CAS  Google Scholar 

  148. Oldham RK, Bartal AH, Yannelli JR et al. (1988) Regional adoptive immunotherapy with IL-2 activated cells in patients with metastatic cancer [abstract]. In: Proc Am Soc Clin Oncol 7: A 667

    Google Scholar 

  149. Kimura H, Yamaguchi Y, Ebara M, Yoskiawa M (1991) Infusion of LAK cells and anticancer drugs with a total implantable port to a patient with metastatic liver and spleen tumors. Gan To Kagaku Ryoho 18:1996–2000

    PubMed  CAS  Google Scholar 

  150. Matsuhashi N, Moriyama T, Nakamura I, Ishikawa T, Ohnishi S, Nakagama H, Imawari M, Takaku F (1990) Adoptive immunotherapy of primary and metastatic liver cancer via hepatic artery catheter (letter). Eur J Cancer 26:1106–1107

    PubMed  CAS  Google Scholar 

  151. Fagan EA, Pulley M, Limb A, Wolstencroft R, Cranenburgh C, DeVinci C, Karani J, Michell M, Nunnerley H, Zama S et al. (1989) Adoptive immunotherapy administered via the hepatic artery and intralesional interleukin-2 in hepatocellular carcinoma. Cancer Treat Rev 16:151–160

    PubMed  Google Scholar 

  152. Komatsu T, Yamauchi K, Furukawa T, Obata H (1990) Transcatheter arterial injection of autologous lymphokine-activated killer (LAK) cells into patients with liver cancers. J Clin Immunol 10:167–174

    PubMed  CAS  Google Scholar 

  153. Keilholz U, Schlag P, Tilgen W, Brado B, Galm F, Gorich J, Kauffmann WGW, Moller P, Schneider S, Hunstein W (1992) Regional administration of lymphokine-activated killer cells can be superior to intravenous application. Cancer 69 : 2172–2175

    PubMed  CAS  Google Scholar 

  154. Medenica R, Huschart T (1991) Intra-arterial/intrahepatic therapy regimen using pharmacosensitivity model in vitro [abstract]. In: Proc Am Soc Clin Oncol 10:A456

    Google Scholar 

  155. Fuchimoto S, Yasui Y, Gouchi A, Hamada F, Sanada E, Urakubo M, Okura M, Akamatsu Y, Sasaki A, Orita K (1988) Favorable response of advanced hepatocellular carcinoma to proper hepatic arterial administration of cytokines and the significance of the administration. Gan To Kagaku Ryoho 15:2396–2400

    PubMed  CAS  Google Scholar 

  156. Hartlapp JH, Hasan I, Gorich J, Schuth J (1993) Intra-arterial injection of interferon in different tumors [abstract]. In: Proc Am Soc Clin Oncol 12: A1376

    Google Scholar 

  157. Daly J, Kemeny N, Sigurdson E, Oderman P, Thorn A (1987) Regional infusion for colorectal hepatic metastases. A randomized trial comparing the hepatic artery with the portal vein. Arch Surg 122:1273–1277

    PubMed  CAS  Google Scholar 

  158. Laufman LR, Nims TA, Guy JT, Guy JF, Courter S (1984) Hepatic artery ligation and portal vein infusion for liver metastases for colon cancer. J Clin Oncol 2 : 1382–1389

    Google Scholar 

  159. Taylor I (1978) Cytotoxic perfusion for colorectal liver metastases. Br J Surg 65: 109–114

    PubMed  CAS  Google Scholar 

  160. Metzger U (1988) Intraportal chemotherapy for colorectal hepatic metastases. Antibiot Chemother 40:51 – 60

    PubMed  CAS  Google Scholar 

  161. Wolmark N, Rockette N, Wickerham D, Fisher B, Redmond C, Fisher ER, Potvin M, Davies RJ, Jones J, Robidoux A et al. (1990) Adjuvant therapy of Dukes’ A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: Preliminary results of the National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 8:1466–1475

    PubMed  CAS  Google Scholar 

  162. Laffer U, Metzger U, Arigoni M et al. (1990)Randomized multicenter trial on adjuvant intraportal chemotherapy for colorectal cancer (SAKK 40/81). In: Jakesz R, Rainer H (Eds) Progress in Regional Cancer Therapy. Berlin/Heidelberg: Springer-Verlag, 31–40

    Google Scholar 

  163. Breedis C, Young G (1954) The blood supply of neoplasms in the liver. Am J Pathol 30:969–985

    PubMed  CAS  Google Scholar 

  164. Ackerman NB, Lien WM, Kondi ES, Silverman NA (1969) The blood supply of experimental liver metastases. 1. The distribution of hepatic artery and portal vein blood to „small“ and „large“ tumors. Surgery 66:1067–1072

    PubMed  CAS  Google Scholar 

  165. Almersjö O, Bengmark S, Engevik L, Hafström LO, Nilsson LA (1966) Hepatic artery ligation as pretreatment for liver resection of metastatic cancer. Rev Surg 23:377–380

    PubMed  Google Scholar 

  166. Nilsson LA (1966) Therapeutic hepatic artery ligation in patients with secondary liver tumors. Rev Surg 23:374–376

    PubMed  CAS  Google Scholar 

  167. Bengmark S, Rosengren K (1970) Angiographic study of the collateral circulation to the liver after ligation of the hepatic artery in man. Am J Surg 119:620–624

    PubMed  CAS  Google Scholar 

  168. Plengvanit V, Chearanai O, Sindhvananda K, Damrongsak D, Tuchinda S, Viranuvatti V (1972) Collateral arterial blood supply of the liver after hepatic artery ligation, angiographic study of 20 patients. Ann Surg 175:105–110

    PubMed  CAS  Google Scholar 

  169. Charnsangavej C, Chuang VP, Wallace S, Soo CS, Bowers T (1982) Angiographic classification of hepatic arterial collaterals. Radiology 144:485–494

    PubMed  CAS  Google Scholar 

  170. Bengmark S, Jeppson B, Nobin A (1988) Arterial ligation and temporary dearterialization. In: Blumgart LH (Ed) Surgery of the Liver and Biliary Tract. New York: Churchill Livingstone, 1219–1235

    Google Scholar 

  171. Xiao-Hua Z, Meng-Chao W (1989) Hepatic artery ligation and operative embolization. In: Zhao-You T, Meng-Chao W, Sui-Sheng X (Eds) Primary Liver Cancer. New York: Springer-Verlag, 385–393

    Google Scholar 

  172. Chuang VP, Wallace S (1981) Arterial infusion and occlusion in cancer patients. Semin Roentgenol 16:13–25

    PubMed  CAS  Google Scholar 

  173. Clouse ME, Lee RG, Duszlak EJ, Lokich JJ, Trey C, Alday MR, Yoburn DC, Diamond J, Crosson QW, Costeollo P (1983) Peripheral hepatic artery embolization for primary and secondary hepatic neoplasms. Radiology 147:407–411

    PubMed  CAS  Google Scholar 

  174. Anderson M, Aronsen KF, Balch C, Domellof L, Eksborg S, Hafstrome LO, Howell SB, Karesen R, Midander J, Teder H (1989) Pharmacokinetics of intraarterial mitomycin C with or without degradable starch microspheres (DSM) in the treatment of non-resectable liver cancer. Acta Oncol 28:219–222

    Google Scholar 

  175. Civalleri D, Esposito M, Fulco RA, Vannozi M, Balletto N, De Cian F, Percivale PL, Merlo F (1991) Liver and tumor uptake and plasma pharmacokinetic of arterial cisplatin administered with and without starch microspheres in patients with liver metastases. Cancer 68:988–994

    PubMed  CAS  Google Scholar 

  176. Venook AP (1994) Treatment of hepatocellular carcinoma: Too many options: J Clin Oncol 12:1323–1334

    PubMed  CAS  Google Scholar 

  177. Chuang VP, Wallace S, Soo CS, Charnsangavej C, Bowers T (1982) Therapeutic Ivalon embolization of hepatic tumors. AJR Am J Roentgenol 138:289–294

    PubMed  CAS  Google Scholar 

  178. Patt YZ, Chuang VP, Wallace S, Benjamin RS, Fuqua R, Mavligit GM (1983) Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver. Cancer 51:1359–1363

    PubMed  CAS  Google Scholar 

  179. Lorenz M, Hottenrott C, Baum RP et al. (1990) Chemoembolization of hepatic tumors with degradable starch microspheres. In: Jakesz R, Rainer H (Eds) Progress in Regional Cancer Therapy. Berlin/Heidelberg: Springer-Verlag, 110–117

    Google Scholar 

  180. Sigurdson ER, Ridge JA, Daly JM (1986) Intra-arterial infusion of doxorubicin with degradable starch microspheres. Arch Surg 121:1277–1281

    PubMed  CAS  Google Scholar 

  181. Ariel IM (1972) Hepatic metastases from rectal and colon cancers. Treatment by infusion of 5-fluorouracil into umbilical vein. NY State J Med 72:2629–2632

    CAS  Google Scholar 

  182. Ariel IM, Padula G (1987) Treatment of symptomatic metastatic cancer to the liver from primary colon and rectal cancer by the intra-arterial administration of chemotherapy and radioactive isotopes. J Surg Oncol 10:327–336

    Google Scholar 

  183. Ariel IM, Padula G (1978) Treatment of symptomatic metastatic cancer to the liver from primary colon and rectal cancer by the intraarterial administration of chemotherapy and radioactive isotopes. Prog Clin Cancer 7:247–254

    PubMed  CAS  Google Scholar 

  184. Blanchard RJ (1978) Precautions in the use of 90Y microspheres. In: Spencer RP, (Ed) Therapy in Nuclear Medicine. New York: Grune and Stratton, 367–370

    Google Scholar 

  185. Grady ED (1979) Internal radiation therapy of hepatic cancer. Dis Colon Rectum 22:371–375

    PubMed  CAS  Google Scholar 

  186. Raoul JL, Bourguet P, Bretagne JF, Duvauferrier R, Coornaert S, Darnault P, Ramee A, Herry JY, Gastard J (1988) Hepatic artery injection of 131I-labelled Lipiodol. Part 1. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiology 168:541–545

    PubMed  CAS  Google Scholar 

  187. Wollner I, Knutsen C, Smith P, Prieskorn D, Chrisp C, Andrews J, Juni J, Warber S, Klevering J, Crudup J et al. (1988) Effects of hepatic arterial yttrium 90 glass microspheres in dogs. Cancer 61:1336–1344

    PubMed  CAS  Google Scholar 

  188. Yumoto Y, Jinno K, Inatsuki S, Moriwaki S, Hanafusa T, Yumoto E, Shiota T, Higashi T, Koide N, Hada H et al. (1992) Treatment of hepatocellular carcinoma by transcatheter hepatic arterial injection of radioactive iodized oil solution. Cancer Chemother Pharmacol 131 (Suppl 1) : S 148–S 136

    Google Scholar 

  189. Aigner KR, Walther H, Link KH (1988) Isolated liver perfusion with MMC/5-FU: Surgical technique, pharmacokinetics, clinical results. Contr Oncol 29:229–246

    Google Scholar 

  190. Aigner KR, Muller H, Walther H, Linh KH (1988) Drug filtration in high dose regional chemotherapy. Contr Oncol 29:261–280

    Google Scholar 

  191. Muchmore JH, Krementz ET, Carter RD et al. (1990) Management of advanced intra-abdominal malignancy using high-dose intra-arterial chemotherapy with concomitant hemofiltration. Reg Cancer Treat 3:211–215

    Google Scholar 

  192. Caillon P, Ducerf C, Tigaud S et al. (1990) High-dose intra-arterial hepatic chemotherapy combined with extra-corporeal haemofiltration of the suprahepatic blood. Reg Cancer Treat 3:216–221

    Google Scholar 

  193. Storm FK, Morton DL (1983) Hyperthermia: Adjunctive modality for hepatic infusion chemotherapy. Semin Oncol 10:223–227

    PubMed  CAS  Google Scholar 

  194. Ramming KP, Storm FK (1988) Hyperthermia and 5-FU therapy for colorectal cancer metastatic to the liver: A prospective randomized study of regional infusion and hepatic artery ligation vs. systemic chemotherapy. Contr Oncol 29:181–192

    Google Scholar 

  195. Skibba JL, Quebbeman EJ, Komorowski RA, Thorsen KM (1988) Clinical results of hyperthermic liver perfusion for cancer in the liver. Contr Oncol 29:222–228

    Google Scholar 

  196. Ku YS, Fukumoto T, Tominaga M, Iwasaki T, Maeda I, Kusunoki N, Obara H, Sako M, Suzuki Y, Kuroda Y, Saitoh Y (1997) Single catheter technique of hepatic venous isolation and extracorporal charcoal hemoperfusion for malignant liver tumors. Am J Surg 173:103–109

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. D. V. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Hoque
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Z. Patt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Jones, D.V., Hoque, A., Patt, Y.Z. (1998). Regionale Therapie hepatischer Tumoren. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10493-4_30

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10493-4_30

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-63821-6

  • Online ISBN: 978-3-662-10493-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation